Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Core Insights - Akero Therapeutics is a clinical-stage company focused on developing treatments for serious metabolic diseases with high unmet medical needs, particularly MASH [2] Group 1: Company Overview - Akero's lead product candidate, EFX, is currently being evaluated in three ongoing Phase 3 clinical trials targeting patients with pre-cirrhotic MASH (F2-F3) and compensated cirrhosis (F4) due to MASH [2] - The SYNCHRONY program builds on the results of two Phase 2b clinical trials, including the completed HARMONY study and the ongoing SYMMETRY study, with over 300 patients treated with EFX or placebo for up to 96 weeks [2] - The company is headquartered in South San Francisco and provides additional information through its website and social media platforms [2] Group 2: Upcoming Events - Management will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025, at 11:15 a.m. P.T. [1] - A live webcast of the presentation will be available on the company's investor relations section, with an archived replay accessible afterward [1]